Genentech Restricts Population In Last-Ditch Bid To Keep Avastin’s Breast Cancer Claim

Genentech’s last-ditch bid to retain Avastin’s metastatic breast cancer claim expands upon discussions at FDA’s June 28-29 hearing about targeted subpopulations and labeling revisions, but breaks little new ground.